StockData
Protagonist Therapeutics, Inc logo

Protagonist Therapeutics, Inc (PTGX) stock

PTGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 12/30199% above fair value
$124.67−0.16 (-0.13%)

Close on Nov 17, 2026Market cap $8.07BP/E 121.0Yield –

Protagonist Therapeutics operating margin

Operating margin is operating income as a percentage of revenue.

Protagonist Therapeutics's operating margin for the twelve months ending Jun 30, 2026 was 20.7%. For fiscal 2025 it was -343.6%, against 58.2% the year before. The highest annual figure on record is 58.2% in fiscal 2024.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-343.6%−401.8
FY2024Dec 31, 202458.2%+214.3
FY2023Dec 31, 2023-156.1%+338.1
FY2022Dec 31, 2022-494.2%−34.2
FY2021Dec 31, 2021-460.0%−234.7
FY2020Dec 31, 2020-225.4%+34632.2
FY2019Dec 31, 2019-34857.6%−34720.9
FY2018Dec 31, 2018-136.7%+52.2
FY2017Dec 31, 2017-188.9%–

Quarterly operating margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 202674.4%+832.4
Q1 FY2026Mar 31, 2026-6.5%+61.7
Q4 FY2025Dec 31, 2025-677.1%−751.4
Q3 FY2025Sep 30, 2025-985.2%−98.5
Q2 FY2025Jun 30, 2025-758.0%+172.9
Q1 FY2025Mar 31, 2025-68.2%−149.1
Q4 FY2024Dec 31, 202474.3%+35.9
Q3 FY2024Sep 30, 2024-886.7%+3937.9
Q2 FY2024Jun 30, 2024-931.0%−848.9
Q1 FY2024Mar 31, 202480.9%+510.5
Q4 FY2023Dec 31, 202338.4%+368.2
Q2 FY2022Jun 30, 2022-4824.6%−3461.1
Q1 FY2022Mar 31, 2022-82.1%+306.1
Q4 FY2021Dec 31, 2021-429.6%−96.3
Q3 FY2021Sep 30, 2021-329.8%−270.6
Q2 FY2021Jun 30, 2021-1363.4%−727.2
Q1 FY2021Mar 31, 2021-388.1%+26.4
Q4 FY2020Dec 31, 2020-333.3%+605.7
Q3 FY2020Sep 30, 2020-59.3%+595.7
Q4 FY2019Dec 31, 2019-636.2%−482.7
Q3 FY2019Sep 30, 2019-414.6%−335.4
Q1 FY2019Mar 31, 2019-939.0%−862.6
Q4 FY2018Dec 31, 2018-655.0%−623.9
Q3 FY2018Sep 30, 2018-153.5%−96.8
Q2 FY2018Jun 30, 2018-79.1%–
Q1 FY2018Mar 31, 2018-76.3%–
Q4 FY2017Dec 31, 2017-31.1%–
Q3 FY2017Sep 30, 2017-56.7%–

More Protagonist Therapeutics figures

See a number that looks wrong?